FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:712-717 August 13, 2009 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The recent controversy about whether the cholesterol-lowering drug ezetimibe causes cancer raises urgent questions about the systems we use to develop drugs and medical devices and then to evaluate their safety and effectiveness.^1,2,3 There is widespread recognition that large, multinational clinical outcomes trials are essential to understanding the risks and benefits of new treatments. Although such studies are dubbed "simple," their organizational complexity entails huge investments of money, time, and energy. Given this context, the events surrounding the development and testing of ezetimibe present a useful opportunity for reflection on the future direction of the clinical research enterprise. We discuss . . . [Full Text of this Article]

Initial Approval of Ezetimibe

Studies Initiated after Completion of Pivotal Trials

Unveiling of the SEAS Results

Discussion

Source Information

From the Duke Translational Medicine Institute (R.M.C.) and the Duke Clinical Research Institute (R.A.H., M.A.B.) — both in Durham, NC.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.